Journal of Cancer Research and Clinical Oncology

, Volume 122, Issue 9, pp 554–558

Phase II study of 5-fluoruracil leucovorin and azidothymidine in patients with metastatic colorectal cancer

  • Jeffrey Clark
  • William Sikov
  • Frank Cummings
  • Marcia Browne
  • Wallace Akerley
  • Harrold Wanebo
  • Alan Weitberg
  • Teresa Kennedy
  • Bernard Cole
  • Joseph Bigley
  • Julie Beitz
  • James Darnowski
Original Paper Clinical Oncology

Abstract

The primary objective of this study was to determine the response rate of patients with metastatic colorectal cancer to combined therapy with 5-fluorouracil (5-FU), leucovorin, and intravenous azidothymidine (AZT), a thymidine nucleoside analog. By itself, AZT has limited antineoplastic efficacy. However, experimental studies indicate that 5-FU enhances the antitumor activity of AZT by inhibiting synthesis of normal thymidine nucleotides with which AZT competes for incorporation into nucleic acids. A phase I study defined the maximum tolerated dose of AZT as 7 g/m2 with hypotension during the infusion being the dose-limiting toxicity. A phase II study was performed with oral leucovorin (100 mg p.o. hourly for 4 h prior to 5-FU and 4 h and 8 h after 5-FU), bolus 5-FU (400 mg/m2) followed 1 h later by a 2-h infusion of AZT (7 g/m2). Treatment was given weekly for 4 weeks followed by a 1-week break, which constituted a cycle of therapy. Responses were evaluated after every two cycles. Patients continued on therapy as long as they tolerated treatment and did not have progressive disease. Of 15 evaluable patients who had received no chemotherapy there was 1 complete response and 4 partial responses (a 33% response rate), whereas only 1 of 6 patients who had received prior adjuvant chemotherapy had a partial response (17%). An additional 10 patients had stable disease lasting 2–14 months. Therapy was well tolerated with the only one instance each of grade 3 nausea and vomiting, diarrhea, anemia, and hypotension. Approximately 50% of treatments were accompanied by mild hypotension, which was easily corrected by increasing the rate of normal saline infusion. There was no difficulty administering this regimen in the outpatient setting. While the overall response rate (29%) is comparable to that seen with combinations of 5-FU and leucovorin alone, in most reported series a considerably higher dose of 5-FU was utilized than in this study. Since patients in the present study experienced relatively little 5-FU toxicity, increasing the dose of 5-FU in this regimen would appear to be feasible and might result in a higher response rate.

Key words

Colon cancer AZT Fluorouracil Leucovorin 

Abbreviations

AZT

Azidothymidine

5-FU

fluorouracil

LV

leucovorin

TS

thymidylate synthase

NS

normal saline

MTD

maximum tolerated dose

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Advanced Colorectal Cancer Meta-analysis Project (1992) Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. J Clin Oncol 10:896–903Google Scholar
  2. Advanced Colorectal Cancer Meta-analysis Project (1994) Meta-analysis of randomized trials testing the biochemical modulation of fluorouracil by methotrexate in metastatic colorectal cancer. J Clin Oncol 12:960–969Google Scholar
  3. Ahmed NK (1984) Enzymes of the de novo and salvage pathways for pyrimidine biosynthesis in normal colon, colon carcinoma, and xenografts. Cancer 54:1370–1373PubMedGoogle Scholar
  4. Arbuck SG (1989) Overview of clinical trials using 5-fluorouracil and leucovorin for the treatment of colorectal cancer. Cancer 63:1036–1044PubMedGoogle Scholar
  5. Beitz JG, Darnowski JW, Cummings FJ, Browne MJ, Clark JW, Bigley JW, Weitberg AB (1995) Phase I trial of high dose infused zidovudine combined with leucovorin plus fluorouracil. Cancer Invest 13:464–469PubMedGoogle Scholar
  6. Broder S, Mitsuya H, Yarchoan R, Pavlakis GN (1990) NIH Conference. Antiretroviral therapy in AIDS. Ann Intern Med 113:604–618PubMedGoogle Scholar
  7. Brunetti I, Falcone A, Calabresi P, Goulette FA, Darnowski JW (1990) 5-Fluorouracil enhances azidothymidine cytotoxicity: in vitro, in vivo and biochemical studies. Cancer Res 50:4028–2031Google Scholar
  8. Cohen AM, Minsky BD, Schilsky RL (1993) Colon cancer. In: DeVita VT Jr, Hellman S, Rosenberg SA (eds) Cancer principles and practice of oncology. Lippincott, Philadelphia, pp 929–977Google Scholar
  9. Copeland WC, Chen MS, Wang TS (1992) Human DNA polymerases alpha and beta are able to incorporate anti-HIV deoxynucleotides into DNA. J Biol Chem 267:21459–21464PubMedGoogle Scholar
  10. Darnowski JW, Goulette FA (1992) Fluorouracil increases azidothymidine cytotoxicity by altering dTTP pools. Proc Am Assoc Cancer Res 33:2511Google Scholar
  11. Darnowski JW Goulette FA (1994) Synergistic cytotoxicity with α-Interferon and azidothymidine in HCT-8 cells reflects increased azidothymidine incorporation in DNA (abstract). Proc Am Assoc Cancer Res 35:1990Google Scholar
  12. Darnowski JW, Renaud CA, Chu M, Goulette F, Tosi P, Calabresi P (1991) Resistance to azidothymidine cytotoxicity in the human colon tumor cell line HCT15 is associated with enhanced removal of AZT from cellular DNA (abstract). Proc Am Assoc Cancer Res 32:2124Google Scholar
  13. Darnowski JW, Hankinson G, Goulette FA (1995) Alpha-interferon induced inhibition of DNA repair increases the cytotoxicity of azidothymidine in HCT-8 cells (abstract). Proc Am Assoc Cancer Res 36:1773Google Scholar
  14. Dupuy J, Price M, Lynch G, Bruce S, Schwartz M (1993) Intralesional interferon-α and zidovudine in epidemic Kaposis sarcoma. J Am Acad Dermatol 28:966–972PubMedGoogle Scholar
  15. Elias L and Crissman HA (1988) Interferon effects upon the adenocarcinoma 38 and HL-60 cell lines. Antiproliferative responses and synergistic interactions with halogenated pyrimidine anti-metabolites. Cancer Res 48:4868–4873PubMedGoogle Scholar
  16. Gill PS, Harrington, Jr W, Kaplan MH, Ribeiro RC, Bennett JM, Liebman HA, Bernstein-Singer M, Espina BM, Cabral L, Allen S, Kornblau S, Pike MC, Levine AM (1995) Treatment of adult T-cell leukemia-lymphoma with a combination of interferon alfa and zidovudine. N Engl J Med 332:1744–1748PubMedGoogle Scholar
  17. Grem JL (1995) Future challenges for the systemic therapy of metastatic colorectal cancer. ASCO Educational Book. American Society of Clinical Oncology, Chicago, pp 55–58Google Scholar
  18. Hermine O, Bouscary D, Gessain A, Turlure P, Lebland V, Franck N, Buzyn-Veil A, Rio B, Macintyre E, Dreyfus E, Bazarbachi A (1995) Brief report: treatment of adult T-cell leukemia-lymphoma with zidovudine and interferon alfa. N Engl J Med 332:1749–1750PubMedGoogle Scholar
  19. Hill M, Norman A, Cunningham D, Findlay M, Nicolson V, Hill A, Iveson A, Evans C, Joffe J, Nicolson M, Hickish T (1995) Royal Marsden phase III trial of fluorouracil with or without interferon alfa-2b in advanced colorectal cancer. J Clin Oncol 13:1297–1302PubMedGoogle Scholar
  20. Kemeny N, Lokich JJ, Anderson N, Ahlgren JD (1993) Recentn advances in the treatment of advanced colorectal cancer. Cancer 71:9–18PubMedGoogle Scholar
  21. Krown SE, Gold JWM, Niedzwiecki D, Bundow D, Flomenberg N, Gansbacher B, Brew BJ (1990) Interferon-α with zidovudine: safety, tolerance, and clinical and virologic effects in patients with Kaposi sarcoma associated with the acquired immunodeficiency syndrome (AIDS). Ann Int Med 112:812–821PubMedGoogle Scholar
  22. Krown SE, Paredes J, Bundow D, Polsky B, Gold JWM, Flomenberg N (1992) Interferon-α, zidovudine, and granulocyte-macrophage colony-stimulating factor: a phase I AIDS clinical trials group study in patients with Kaposi's sarcoma associated with AIDS. J Clin Oncol 10:1344–1351PubMedGoogle Scholar
  23. Moran RG (1989) Leucovorin enhancement of the effects of fluoropyrimidines on thymidylate synthase. Cancer 63:1008–1012PubMedGoogle Scholar
  24. Paterson ARP, Kolassa N, Cass CE (1981) Transport of nucleoside drugs in animal cells. Pharmacol Ther 12:516–536Google Scholar
  25. Podzamczer D, Bolao F, Clotet B, Garcia P, Casanova A, Pagerols X, Gudiol F (1993) Low-dose interferon alpha combined with zidovudine in patients with AIDS associated Kaposi's sarcoma. J Intern Med 233:247–253PubMedGoogle Scholar
  26. Poon MA, O'Connell MJ, Moertel CG, Wieand HS, Cullnan SA, Everson LK, Krook JE, Mailliard JA, Laurie JA, Tschetter LK, Wiesenfeld M (1989) Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol 7:1407–1418PubMedGoogle Scholar
  27. Posner MR, Darnowski JW, Calabresi P, Brunetti I, Corvese D, Curt G, Clark JW, Browne MJ, Beitz J, Weitberg AB (1990) Oral azidothymidine, continuous infusion 5-fluorouracil and oral leucovorin: a phase I study. J Natl Cancer Inst 82:1710–1714PubMedGoogle Scholar
  28. Posner MR, Darnowski JW, Weitberg AB, Dudley MN, Corvese D, Cummings FJ, Clark J, Murray C, Clendennin N, Bigley J, Calabresi P (1992) High-dose intravenous zidovudine with 5-fluorouracil and leucovorin. Cancer 70:2929–2934PubMedGoogle Scholar
  29. Preiss J (1992) Fluorouracil plus interferon + folinic acid in regional and systemic therapy in colorectal cancer. Semin Oncol 19 [Suppl 3]:220–224Google Scholar
  30. Pressacco J, Erlichman C (1993) Combination studies with 3′-azido-3′-deoxythymidine (AZT) plus ICI D1694. Cytotoxic and biochemical effects. Biochem Pharmacol 46:1989–1997PubMedGoogle Scholar
  31. Raderer M, Scheithauer W (1995) Treatment of advanced colorectal cancer with 5-fluorouracil and interferon-α: an overview of clinical trials. Eur J Cancer 31A:1002–1008PubMedGoogle Scholar
  32. Slichenmyer WJ, Rowinsky EK, Donehower RC, Kaufmann SH (1993) The current status of camptothecin analogues as antitumor agents. J Natl Cancer Inst 85:271–291PubMedGoogle Scholar
  33. Tosi P, Visani G, Ottaviani E, Gamberi B, Cenacchi A, Tura S (1993) Synergistic cytotoxicity of AZT plus alpha and gamma Interferon in chronic myeloid leukemia cell line K562. Eur J Haematol 51:209–213PubMedGoogle Scholar
  34. Wadler S, Wersto R, Weinberg V, Thompson D, Sewartz EL (1990) Interaction of Fluorouracil and Interferon in human colon cancer cell lines. Cytotoxic and cytokinetic effects. Cancer Res 50:5735–5739PubMedGoogle Scholar
  35. Weber G, Ichikawa S, Nagai M, Natsumeda Y (1990) Azidothymidine inhibition of thymidine kinase and synergistic cytotoxicity with methotrexate and 5-fluorouracil in rat hepatoma and human colon cancer cells. Cancer Commun 2:129–133PubMedGoogle Scholar
  36. Wilde MI, Lantry HD (1993) Zidovudine. An update of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs 46:515–578PubMedGoogle Scholar
  37. Zhen YS, Taniki T, Weber G (1992) Azidothymidine and dipyrimidole as biochemical response modifiers: synergism with methotrexate and 5-fluorouracil in human colon and pancreatic carcinoma cells. Oncol Res 4:73–78PubMedGoogle Scholar

Copyright information

© Springer-Verlag 1996

Authors and Affiliations

  • Jeffrey Clark
    • 1
  • William Sikov
    • 1
  • Frank Cummings
    • 1
  • Marcia Browne
    • 1
  • Wallace Akerley
    • 1
  • Harrold Wanebo
    • 1
  • Alan Weitberg
    • 1
  • Teresa Kennedy
    • 1
  • Bernard Cole
    • 1
  • Joseph Bigley
    • 2
  • Julie Beitz
    • 1
  • James Darnowski
    • 1
  1. 1.Brown University Clinical Oncology GroupProvidenceUSA
  2. 2.Burroughs WellcomeResearch Park TriangleUSA
  3. 3.MGH Cancer CenterBostonUSA

Personalised recommendations